EUVIMEDEUVIMED entdecken
Crossref

Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study

C Warren Olanow iD, Deborah McIntyre, Michele Matarazzo iD, Mika Leinonen, Andrew McGarry, Cornelia Kamp, Julie Kennedy, Margherita Torti, Rejko Kruger, José A Obeso, Fabrizio Stocchi iD, Ephraim Heller und 1 weitere

Movement Disorders · 2024-06 · 39 (6) · 945-954

DOI: 10.1002/mds.29824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 02.05.2024. Verfasst von C Warren Olanow und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Antiparkinson Agents, Carbidopa, Levodopa, Parkinson Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Double‐blind studies have demonstrated that motor complications in Parkinson's disease (PD) can be reduced with continuous delivery of levodopa. The DopaFuse system is a novel, intraoral micropump that attaches to a retainer and uses a propellant to deliver levodopa/carbidopa (LD/CD) continuously into the mouth.

Objectives

Evaluate the safety, pharmacokinetics, and efficacy of LD/CD delivered via the DopaFuse system compared to treatment with intermittent doses of standard oral LD/CD in PD patients with motor fluctuations.

Methods

This was a 2‐week, open‐label study (NCT04778176) in 16 PD patients treated with ≥4 levodopa doses/day and experiencing motor fluctuations. On Day 1 (clinic setting) patients received their usual dose of standard LD/CD; DopaFuse therapy was initiated on Day 2, and on Day 3 patients received DopaFuse plus a morning oral LD/CD dose. Patients returned home on Days 4–14 and returned for in‐clinic assessment on Day 15.

Results

Continuous DopaFuse delivery of LD/CD was associated with reduced variability in plasma levodopa levels compared to oral LD/CD (mean ± SD levodopa Fluctuation Index reduced from 2.15 ± 0.59 on Day1 to 1.50 ± 0.55 on Day 2 ( P = 0.0129) and to 1.03 ± 0.53 on Day 3 ( P < 0.0001)). This pharmacokinetic improvement translated into significantly reduced OFF time with DopaFuse therapy (reduction of −1.72 ± 0.37 h at Day 15; P = 0.0004) and increased ON time without severe dyskinesias (increase of 1.72 ± 0.37 h at Day 15; P = 0.0004) versus oral LD/CD administration. DopaFuse therapy was not associated with any clinically significant adverse events.

Conclusions

Continuous delivery of LD/CD using the DopaFuse system was associated with significantly less variability in plasma levodopa concentrations and reductions in OFF time compared to treatment with standard oral LD/CD therapy and was well tolerated. © 2024 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiparkinson AgentsCarbidopaLevodopaParkinson DiseaseAgedFemaleHumansMaleMiddle AgedDrug CombinationsTreatment Outcome

Stichwörter der Autor:innen

DopaFuseParkinson's diseasecontinuous deliveryintraoralmicropumpmotor fluctuationsretainer

Substanzen

Antiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsLevodopa

Autor:innen und Institutionen

  • Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA.
  • Clintrex Research Corporation, Sarasota, Florida, USA.
  • Luxembourg Institute of Health, Transversal Translational Medicine, Strassen, Luxembourg.
  • Centro Integral de Neurociencias AC (CINAC), Hospital Universitario HM Puerta del Sur, Fundación de Investigación HM Hospitales, Madrid, Spain.
  • Cooper Medical School of Rowan University, Camden, New Jersey, USA.
  • Center for Health & Technology, University of Rochester, Rochester, New York, USA.

ORCID-Profile: C Warren Olanow, Michele Matarazzo, Fabrizio Stocchi

Zitieren

APA

Olanow, C. W., McIntyre, D., Matarazzo, M., Leinonen, M., McGarry, A., Kamp, C., Kennedy, J., Torti, M., Kruger, R., Obeso, J. A., Stocchi, F., Heller, E., & Kieburtz, K. (2024). Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study. Movement Disorders, 39(6), 945-954. https://doi.org/10.1002/mds.29824

Vancouver

Olanow CW, McIntyre D, Matarazzo M, Leinonen M, McGarry A, Kamp C, et al. Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study. Movement Disorders. 2024;39(6):945-954. doi:10.1002/mds.29824

BibTeX
@article{Olanow2024,
  author = {Olanow, C Warren and McIntyre, Deborah and Matarazzo, Michele and Leinonen, Mika and McGarry, Andrew and Kamp, Cornelia and Kennedy, Julie and Torti, Margherita and Kruger, Rejko and Obeso, José A and Stocchi, Fabrizio and Heller, Ephraim and Kieburtz, Karl},
  title = {Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study},
  journal = {Movement Disorders},
  year = {2024},
  volume = {39},
  number = {6},
  pages = {945--954},
  doi = {10.1002/mds.29824}
}
Kostenlos starten →